14 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 10 Phase 1, 7 Phase 2, 7 Phase 3, 1 Not applicable.
Follow Placebo oral solution: new trials by email Literature Review of Placebo oral solution trials Research Report on Placebo oral solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-31 | 2026-04-14 |
| A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects TLC-1180 Oral Solution, TLC-1180 Tablet, Placebo Oral Solution - Healthy Participants | Phase 1 | Recruiting | OrsoBio, Inc | 332 | 2025-10-20 | 2026-08-21 |
| CBD for Pain Following Orthopedic Shoulder Surgery Epidiolex, Placebo oral solution - Shoulder Osteoarthritis, Rotator Cuff Injuries | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 80 | 2024-05-24 | 2026-04-16 |
| Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes TLC-6740 Oral Solution, Placebo Oral Solution, TLC-6740 Tablet - Healthy Subjects, Obesity | Phase 1 | Active not recruiting | OrsoBio, Inc | 564 | 2023-04-22 | 2026-08-21 |
| Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder Cannabidiol (CBD) oral solution, Placebo, Massed Prolonged Exposure (mPE) - Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 21 | 2022-04-04 | 2024-10-10 |
| Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease Eefooton oral solution, Placebo oral solution - Chronic Kidney Diseases, Renal Insufficiency, Chronic | Not applicable | Unknown | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 120 | 2022-03-01 | 2022-03-02 |
| Efficacy of Adaptogens in Patients With Long COVID-19 ADAPT-232 oral solution, Placebo oral solution - Covid19 | Phase 2 / Phase 3 | Completed | Swedish Herbal Institute AB | 100 | 2021-04-19 | 2021-12-28 |
| Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers CRN04894 Oral Solution, Placebo Oral Solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 88 | 2020-12-18 | 2023-09-21 |
| A Phase 1 Study of SMP-100 in Normal Healthy Volunteers SMP-100, Placebo - Healthy Volunteers | Phase 1 | Completed | Chengdu SciMount Pharmatech Co., Ltd. | 53 | 2020-06-25 | 2022-03-11 |
| A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP AZP2006 oral solution, Placebo oral solution - Progressive Supranuclear Palsy | Phase 2 | Completed | AlzProtect SAS | 36 | 2020-06-22 | 2025-03-17 |
| Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism Epidiolex, placebo oral solution - Autism, Autism Spectrum Disorder | Phase 2 | Active not recruiting | University of California, San Diego | 42 | 2020-06-01 | 2025-09-30 |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | University of Edinburgh | 1150 | 2020-02-27 | 2026-03-04 |
| Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants BAY2395840 tablet, BAY2395840 oral solution, Placebo oral solution - Endometriosis | Phase 1 | Completed | Bayer | 63 | 2019-12-18 | 2022-08-26 |
| A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970 GLPG3970 oral solution, Placebo oral solution, GLPG3970 capsule - Healthy, Psoriasis | Phase 1 | Completed | Lakefront Biotherapeutics NV | 100 | 2019-09-10 | 2024-09-19 |
| A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers CRN01941 Oral Solution, CRN01941 Oral Capsule, Placebo Oral Solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 57 | 2019-04-29 | 2020-11-04 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension JZP-258, Placebo Oral Solution - Idiopathic Hypersomnia | Phase 3 | Completed | Jazz Pharmaceuticals | 154 | 2018-11-27 | 2021-11-24 |
| Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome Aripiprazole Oral Solution, Placebo Oral Solution - Tourette Syndrome | Phase 3 | Completed | Otsuka Beijing Research Institute | 121 | 2018-05-02 | 2020-12-29 |
| Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder Aripiprazole Oral Solution, Placebo Oral Solution - Autistic Disorder | Phase 3 | Completed | Otsuka Beijing Research Institute | 111 | 2018-04-09 | 2020-12-29 |
| Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers CRN00808, Placebo Oral Solution, Midazolam oral solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 99 | 2017-09-22 | 2018-08-29 |
| A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults FE 201836, Desmopressin, Placebo oral solution - Nocturia | Phase 2 | Completed | Ferring Pharmaceuticals | 302 | 2017-07-27 | 2022-03-02 |
Showing 20 of 21. Sign in to see all of them.
Autistic Disorder (2) · Alopecia (1) · Amyotrophic Lateral Sclerosis (1) · Anxiety Disorders (1) · Autism Spectrum Disorder (1) · COVID-19 (1) · Cognition Disorders (1) · Depression (1) · Diabetes Mellitus, Type 2 (1) · Endometriosis (1) · Epilepsy (1) · Epilepsy, Idiopathic Generalized (1) · Fatigue (1) · Headache (1) · Idiopathic Hypersomnia (1)
Crinetics Pharmaceuticals Inc. (3) · OrsoBio, Inc (2) · Otsuka Beijing Research Institute (2) · AlzProtect SAS (1) · Bayer (1) · Chengdu SciMount Pharmatech Co., Ltd. (1) · Eurofarma Laboratorios S.A. (1) · Ferring Pharmaceuticals (1) · Jazz Pharmaceuticals (1) · Lakefront Biotherapeutics NV (1) · Swedish Herbal Institute AB (1) · Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (1) · The Methodist Hospital Research Institute (1) · The University of Texas Health Science Center at San Antonio (1) · UCB BIOSCIENCES, Inc. (1)
United States (7) · Australia (4) · Belgium (4) · China (3) · Czechia (3) · France (3) · Germany (3) · Poland (3) · Hungary (2) · New Zealand (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Brazil (1) · Bulgaria (1)
Patyman Juma (2) · Casey Straud, PsyD (1) · Chen-Shiung Wu, Ph.D (1) · Ching-Hsiu Peng, MD (1) · Ding-Jun Lin Lin, MD (1) · Doris Trauner, MD (1) · Irina Karosanidze, PhD, MD (1) · Jason Lickliter, MBBS PhD (1) · Ko-Lin Kuo, MD (1) · Kuo-Cheng Lu, Ph.D (1) · Magdalena Petkova, MD (1) · Patrick McCulloch, MD (1) · Philippe Verwaerde, PhD (1)
PMID 34942138, PMID 35000098, PMID 35798516, PMID 36647114, PMID 36725099, PMID 37409509, PMID 39026306, PMID 39307154, PMID 40135693, PMID 40410546, PMID 41442817, PMID 42382222
2019 (2), 2016 (1), 2018 (1), KL2TR002646 (1), UL1TR002645 (1)